Tirzepatide hasnt been compared to the higher dose of semaglutide (Wegovy) now available
Indeed, in the cardiovascular outcome trial (CVOT) for semaglutide, SUSTAIN 6 a relatively short (two-year) and small (3,297 individuals) preregistration trial (an extensive CVOT in obese individuals without T2DM (SELECT) is expected to complete in 2024) HbA 1c was powerfully and durably reduced
Commonly prescribed medications from this drug class (GLP-1 receptor agonists) include semaglutide (Ozempic, Wegovy), liraglutide (Victoza, Saxenda), and tirzepatide (Mounjaro, Zepbound)
These risks have been studied extensively, monitored, and are manageable through dose escalation protocols and patient education
Zinman B, Wanner C, Lachin JM, et al
Looking to build a winning obesity strategy